BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,226,213 | -29.5% | 18,014 | -15.4% | 0.00% | -33.3% |
| Q2 2023 | $1,738,229 | -8.3% | 21,294 | -16.7% | 0.00% | 0.0% |
| Q1 2023 | $1,895,925 | -28.4% | 25,555 | -20.0% | 0.00% | -40.0% |
| Q4 2022 | $2,647,519 | -61.2% | 31,944 | +33.1% | 0.01% | -64.3% |
| Q3 2022 | $6,819,000 | -36.2% | 24,009 | -22.1% | 0.01% | +40.0% |
| Q2 2022 | $10,690,000 | -47.0% | 30,839 | -33.8% | 0.01% | -33.3% |
| Q1 2022 | $20,167,000 | -2.5% | 46,569 | +16.4% | 0.02% | +7.1% |
| Q4 2021 | $20,693,000 | +77.7% | 40,000 | +66.5% | 0.01% | +55.6% |
| Q3 2021 | $11,644,000 | +1346.5% | 24,028 | +1244.6% | 0.01% | +800.0% |
| Q2 2021 | $805,000 | +213.2% | 1,787 | +165.1% | 0.00% | – |
| Q1 2021 | $257,000 | -20.2% | 674 | -44.8% | 0.00% | – |
| Q2 2020 | $322,000 | +19.3% | 1,221 | -14.4% | 0.00% | – |
| Q1 2020 | $270,000 | -84.6% | 1,426 | -82.2% | 0.00% | -100.0% |
| Q4 2019 | $1,756,000 | +1.0% | 8,003 | -9.9% | 0.00% | 0.0% |
| Q3 2019 | $1,738,000 | +34.9% | 8,883 | +43.8% | 0.00% | +100.0% |
| Q2 2019 | $1,288,000 | -70.1% | 6,179 | -71.5% | 0.00% | -75.0% |
| Q1 2019 | $4,308,000 | +17.3% | 21,699 | -14.8% | 0.00% | 0.0% |
| Q4 2018 | $3,672,000 | -50.0% | 25,481 | -29.1% | 0.00% | -42.9% |
| Q3 2018 | $7,337,000 | -41.6% | 35,948 | -57.7% | 0.01% | -41.7% |
| Q2 2018 | $12,574,000 | +23.2% | 84,981 | +25.8% | 0.01% | +20.0% |
| Q1 2018 | $10,205,000 | +76.8% | 67,565 | +51.6% | 0.01% | +100.0% |
| Q4 2017 | $5,773,000 | +7.1% | 44,565 | 0.0% | 0.01% | 0.0% |
| Q3 2017 | $5,388,000 | +3.1% | 44,565 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $5,228,000 | +14.3% | 44,565 | -1.2% | 0.01% | +25.0% |
| Q1 2017 | $4,574,000 | +29.2% | 45,100 | +31.0% | 0.00% | +33.3% |
| Q4 2016 | $3,539,000 | -8.0% | 34,415 | -3.1% | 0.00% | -25.0% |
| Q3 2016 | $3,845,000 | +28.4% | 35,515 | +33.7% | 0.00% | +33.3% |
| Q2 2016 | $2,995,000 | +810.3% | 26,560 | +695.2% | 0.00% | – |
| Q2 2015 | $329,000 | -4.1% | 3,340 | -2.3% | 0.00% | – |
| Q1 2015 | $343,000 | +357.3% | 3,417 | +318.2% | 0.00% | – |
| Q4 2014 | $75,000 | – | 817 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |